Biogen Inc. Stock price

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
216.3 USD +2.04% Intraday chart for Biogen Inc. -0.83% -16.40%
Sales 2024 * 9.48B Sales 2025 * 9.61B Capitalization 31.45B
Net income 2024 * 1.89B Net income 2025 * 2.27B EV / Sales 2024 * 3.6 x
Net Debt 2024 * 2.64B Net Debt 2025 * 413M EV / Sales 2025 * 3.32 x
P/E ratio 2024 *
16.4 x
P/E ratio 2025 *
13.9 x
Employees 7,570
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.34%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.04%
1 week-0.83%
Current month-0.30%
1 month-3.39%
3 months-17.41%
6 months-15.99%
Current year-16.40%
More quotes
1 week
211.02
Extreme 211.015
221.30
1 month
211.02
Extreme 211.015
230.22
Current year
211.02
Extreme 211.015
268.30
1 year
211.02
Extreme 211.015
319.76
3 years
187.16
Extreme 187.16
468.55
5 years
187.16
Extreme 187.16
468.55
10 years
187.16
Extreme 187.16
480.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 22-11-13
Director of Finance/CFO 60 20-08-14
Chief Operating Officer - 14-12-31
Members of the board TitleAgeSince
Director/Board Member 75 09-12-31
Director/Board Member 70 19-06-18
Chairman 64 10-01-02
More insiders
Date Price Change Volume
24-03-27 216.3 +2.04% 1,250,002
24-03-26 212 -2.16% 1,589,940
24-03-25 216.7 -0.65% 725,946
24-03-22 218.1 -1.20% 1,071,072
24-03-21 220.8 +1.19% 1,001,255

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (78.5%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (16.7%) ; - other (4.8%): primarily revenues from partnership agreements.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
216.3 USD
Average target price
299.6 USD
Spread / Average Target
+38.50%
Consensus
  1. Stock
  2. Equities
  3. Stock Biogen Inc. - Nasdaq